Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
Start here
The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.
Excerpted from nature.com
Coverage timeline
Follow the coverage to see the different angles.
- nature.comRelatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
The 5-year analysis of the phase 3 RELATIVITY-047 trial showed statistically significant differences in progression-free survival, overall survival, and melanoma-specific survival between relatlimab plus nivolumab and nivolumab alone in advanced melanoma.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 08:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.